385 related articles for article (PubMed ID: 16421420)
21. Oral regimen for metastatic neuroendocrine tumours.
Kerr C
Lancet Oncol; 2006 Mar; 7(3):197. PubMed ID: 16538777
[No Abstract] [Full Text] [Related]
22. Temozolomide and thalidomide in the treatment of glioblastoma multiforme.
Riva M; Imbesi F; Beghi E; Galli C; Citterio A; Trapani P; Sterzi R; Collice M
Anticancer Res; 2007; 27(2):1067-71. PubMed ID: 17465245
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Shah MH; Young D; Kindler HL; Webb I; Kleiber B; Wright J; Grever M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6111-8. PubMed ID: 15447997
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Zhao J; Zhao H; Chi Y
Neuroendocrinology; 2018; 106(4):318-323. PubMed ID: 28817826
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Abdel-Rahman O; Fouad M
Future Oncol; 2015; 11(8):1275-90. PubMed ID: 25832882
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.
Maire F; Hammel P; Faivre S; Hentic O; Yapur L; Larroque B; Couvelard A; Zappa M; Raymond E; Lévy P; Ruszniewski P
Neuroendocrinology; 2009; 90(1):67-72. PubMed ID: 19521065
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
[TBL] [Abstract][Full Text] [Related]
29. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Schwarzberg AB; Stover EH; Sengupta T; Michelini A; Vincitore M; Baden LR; Kulke MH
Cancer Invest; 2007 Jun; 25(4):249-55. PubMed ID: 17612935
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
[TBL] [Abstract][Full Text] [Related]
31. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with thalidomide, temozolomide and tamoxifen improves quality of life in patients with malignant astrocytomas.
Rabbani G; Benzil D; Wallam MN; Chen B; Hoang A; Kancherla R; Ahmed T
Anticancer Res; 2007; 27(4C):2729-36. PubMed ID: 17695439
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Krown SE; Niedzwiecki D; Hwu WJ; Hodgson L; Houghton AN; Haluska FG;
Cancer; 2006 Oct; 107(8):1883-90. PubMed ID: 16986123
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
35. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
36. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Su YB; Sohn S; Krown SE; Livingston PO; Wolchok JD; Quinn C; Williams L; Foster T; Sepkowitz KA; Chapman PB
J Clin Oncol; 2004 Feb; 22(4):610-6. PubMed ID: 14726505
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
[TBL] [Abstract][Full Text] [Related]
38. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Laber DA; Khan MI; Kloecker GH; Schonard C; Taft BS; Salvador C
Cancer Biol Ther; 2007 Jun; 6(6):840-5. PubMed ID: 17582215
[TBL] [Abstract][Full Text] [Related]
39. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
40. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
